Ivermectol
Ivermectol Price range: $ 67,00 through $ 872,00
Back to products
Kaletra
Kaletra Price range: $ 270,00 through $ 1 423,00

Iversun

Price range: $ 250,00 through $ 500,00

Iversun is a highly effective antiparasitic medication designed to treat specific infections caused by internal and external parasites. This treatment is primarily utilized to eliminate parasitic worms, including those responsible for intestinal strongyloidiasis and onchocerciasis. The active component works by paralyzing and killing the invading organisms, effectively clearing the infection from the body. Available in convenient tablet form, it provides a reliable solution for managing various parasitic conditions and improving systemic health. Consistent use as directed helps restore physical well-being by targeting the root cause of the parasitic infestation.

Active substance: Ivermectin
SKU: Iversun Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Iversun – Information for Patients and Caregivers

Iversun belongs to a group of medicines known as anthelmintics, formulated with the active substance ivermectin. It is indicated for the targeted management of specific parasitic infections and is dispensed in accordance with applicable federal and state prescription regulations in the United States. Healthcare providers evaluate individual patient context to determine appropriate clinical utility and dosage design.

Proper administration requires strict adherence to professional guidance to ensure therapeutic effectiveness while minimizing potential adverse reactions. Patients should review all clinical directives provided by their prescribing physician prior to initiating therapy with this medication.

Attribute Specification
Active ingredient (INN) Ivermectin
Therapeutic class Anthelmintic agent
Dosage form Oral tablet
Route of administration Oral
Primary purpose Treatment of specific parasitic worm infections
Administration requirement Take on an empty stomach with water
Storage conditions Store at room temperature below 86°F (30°C)

How the drug works

The therapeutic action of Iversun relies on the high-affinity binding of its active component, ivermectin, to glutamate-gated chloride ion channels present in invertebrate nerve and muscle cells. This interaction increases the cell membrane’s permeability to chloride ions, causing hyperpolarization of the nerve or muscle cell. Consequently, the targeted parasites experience neuromuscular paralysis and subsequent death. Mammalian tissue remains largely unaffected because human cells lack glutamate-gated chloride channels, and ivermectin does not readily cross the blood-brain barrier under normal physiological conditions when administered at recommended dosages.

Main uses

Iversun is primarily prescribed for the treatment of intestinal strongyloidiasis caused by the nematode parasite Strongyloides stercoralis. It is also indicated for the control of onchocerciasis (river blindness) caused by the parasitic worm Onchocerca volvulus. Off-label applications, such as the treatment of sarcoptic scabies (*Sarcoptes scabiei*), may be designated by healthcare providers based on clinical judgment, though such uses represent off-label prescribing outside standard FDA-approved labeling. Iversun is not approved by the FDA for the prevention or treatment of viral infections, including COVID-19, and must only be utilized for verified parasitic conditions.

Dosing schedule

The dosage of Iversun is calculated based on body weight and the specific parasitic infection undergoing treatment. For intestinal strongyloidiasis, the single oral dose typically delivers approximately 200 micrograms of ivermectin per kilogram of body weight. For onchocerciasis, the standard single oral dose delivers approximately 150 micrograms per kilogram of body weight, which may be repeated at 3- to 12-month intervals based on ongoing clinical evaluation. All doses must be swallowed whole with water on an empty stomach, at least one hour before or two hours after a meal, to ensure predictable systemic absorption.

What happens in the body

Following oral ingestion, Iversun is absorbed through the gastrointestinal tract, reaching peak plasma concentration approximately 4 hours after administration. The active substance exhibits high plasma protein binding, estimated at approximately 93%, predominantly to albumin. Ivermectin undergoes hepatic metabolism mediated primarily by cytochrome P450 enzymes, specifically the CYP3A4 isoenzyme. The terminal elimination half-life in human adults is approximately 18 hours. Elimination occurs almost exclusively through the feces over a period of 12 days, with less than 1% excreted unchanged in urine.

Compatibility with other medicines

Co-administration of Iversun with medications that modulate the cytochrome P450 system may alter systemic exposure. Strong inhibitors or inducers of CYP3A4 can potentially affect plasma concentrations of ivermectin. Concomitant administration with drugs that enhance GABAergic neurotransmission, such as benzodiazepines, barbiturates, or valproic acid, requires careful clinical consideration due to potential additive central nervous system effects. Additionally, concurrent use with oral anticoagulants like warfarin may necessitate periodic monitoring of prothrombin time or International Normalized Ratio (INR) levels. Patients must disclose all active medications to their clinical provider.

Adverse reactions

The side effect profile of Iversun depends on the underlying parasitic infection being treated. In patients treated for strongyloidiasis, reported adverse reactions include dizziness, nausea, diarrhea, abdominal pain, asthenia, and mild skin rash or pruritus. When treating onchocerciasis, systemic reactions (often referred to as the Mazzotti reaction) commonly occur due to immune responses triggered by dying microfilariae. These symptoms include fever, joint pain, muscle aches, lymph node tenderness, tachycardia, and peripheral edema. Most reactions are mild to moderate and self-limiting. Severe allergic reactions remain rare but require immediate evaluation.

Important precautions

Comprehensive patient screening is required before initiating therapy with Iversun. Patients with severe microfilarial burdens, particularly those co-infected with Loa loa in hyperendemic regions, face an increased risk of severe encephalopathy or toxic reactions following microfilarial clearance. Neurological conditions that compromise the blood-brain barrier may increase the risk of central nervous system toxicity. Diagnostic monitoring, including follow-up stool examinations or skin snip biopsies, should be performed as directed by the prescribing physician to confirm parasitic eradication and monitor overall recovery.

Special populations

Safety and effectiveness in pediatric patients weighing less than 15 kg (33 lbs) have not been established. In pregnant patients, Iversun should be administered only if the potential therapeutic benefit justifies the potential risk to the fetus, as adequate and well-controlled clinical studies in pregnant women are limited. Ivermectin is excreted in human breast milk in low concentrations; caution should be exercised when prescribing to nursing mothers. Elderly patients generally receive standard weight-based dosages unless concurrent renal, hepatic, or cardiac dysfunction dictates clinical modifications.

What to avoid while taking it

Food consumption significantly increases the bioavailability of oral ivermectin. Therefore, Iversun should strictly be administered on an empty stomach with a full glass of water to maintain consistent pharmacokinetic parameters. Alcohol consumption should be avoided during treatment, as ethanol may potentiate central nervous system side effects such as dizziness, lightheadedness, and drowsiness, and may increase metabolic strain on hepatic pathways.

If you skip a dose

Because Iversun is frequently prescribed as a single-dose regimen for conditions like strongyloidiasis, missing a dose typically involves delaying the primary therapeutic step. If a prescribed single dose is missed, the patient should contact their prescribing provider to reschedule administration. Patients should take the missed dose on an empty stomach as soon as advised. Never double the dose or take extra tablets to compensate for a missed administration.

Storage and expiration

Store Iversun tablets at controlled room temperature between 68°F and 77°F (20°C to 25°C), with permitted excursions between 59°F and 86°F (15°C to 30°C). Protect the container from excessive light, heat, and moisture. Store the medication out of reach of children and domestic pets. Do not use tablets beyond the expiration date stamped on the package. Dispose of unused or expired medication in accordance with local pharmacy disposal protocols.

Q&A

Is a single dose of Iversun sufficient to eliminate the infection?

For intestinal strongyloidiasis, a single weight-based dose is frequently adequate to clear the infection; however, follow-up stool examinations at 1, 3, and 6 months are necessary to verify complete eradication. In contrast, onchocerciasis requires repeated dosing schedules at intervals of 3 to 12 months because ivermectin kills microfilariae but does not destroy adult worms.

What should I do if I experience dizziness after taking Iversun?

Dizziness is a recognized side effect of ivermectin therapy. If dizziness occurs, sit or lie down immediately until the sensation passes. Avoid driving, operating heavy machinery, or engaging in tasks requiring mental sharpness until full alertness returns. If dizziness persists or worsens, contact your healthcare provider.

Why must Iversun be taken strictly on an empty stomach?

Ingesting Iversun alongside food markedly increases systemic absorption into the bloodstream. While increased exposure might sound beneficial, high absorption levels alter the predictable therapeutic safety window established in clinical studies, increasing the risk and intensity of potential adverse side effects.

How does a clinician confirm that the medication has worked effectively?

Efficacy is determined using post-treatment diagnostic evaluations. For intestinal strongyloidiasis, microscopic examination of stool specimens is conducted to confirm the absence of larvae. For onchocerciasis, skin snip biopsies or specialized ocular examinations assess microfilarial clearance over defined time intervals.

What symptoms indicate a severe adverse reaction requiring immediate care?

Immediate emergency medical care is necessary if a patient displays signs of a severe allergic reaction (such as swelling of the face, lips, tongue, or throat, or difficulty breathing), sudden severe skin eruptions, visual changes, rapid heart rate, intense dizziness leading to fainting, or high fever accompanied by confusion.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

12mg

Package

100 pills

,

200 pills

,

300 pills

Ενεργός Ουσία